

SECTION [0016] delete "11-Hydroxy-yangonin" and accompanying drawing

SECTION [0016] delete "Hydroxykavain" and accompanying drawing

SECTION [0016] delete "11-Methoxy-12-hydroxy-dehydrokavain" and accompanying drawing

CLAIMS

Claim 1

line 2 add -in need thereof- between mammal and a

line 8 delete "an alkyl radical having from 1 to 4 carbon atoms or"


line 9 delete "optionally"

line 10 delete "or one or two hydroxyl groups and/or one or two alkoxy radicals having from 1 to 4 carbon atoms with the proviso that, when R2 is a hydroxyl group, then R3 is necessarily and unsubstituted phenethyl radical with the proviso that when R3 is an alkyl radical having 1 to 4 carbon atoms, then R1 and R2 cannot both be hydrogen"

Dear Mr. Goldberg

According to your office communication dated 06/06/2002 you stated that the alpha-pyrone compounds with the methylenedioxy radical is classified in class 514, subclass 464. However, on the patent application publication dated 11/21/2002 the subclass is listed as 456.

Respectfully Submitted,



Gregory Gene Steiner


Phone: 949 306 9491

email: ggsteiner@yahoo.com


Address: PO box 61515

Honolulu, Hi. 96839


[0016] Among the alpha-pyrone compounds comprising the therapeutic compositions of the invention are the following:



Methysticin



Dihydromethysticin




5,6-Dehydromethysticin

CLAIMS

Claim 1 should read as follows:

1. A method of chemopreventing cancer by administering to a mammal in need thereof a cancer chemopreventive composition of matter, comprising an effective amount of at least one alpha-pyrone compound having the following structural formula:



in which R1 is a hydrogen atom or an alkoxy radical having 1 to 4 carbon atoms, R2 is a hydrogen atom or a hydroxyl group, and R3 is a styryl or phenethyl radical substituted by one or two methylenedioxy radicals in a physiologically acceptable carrier medium for the purpose of preventing cancer sensitive to the formula.